Clinical Trial

Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of RM-004 for Hemoglobin H-Constant Spring disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-25.
Trial Details
NCT Number NCT06107400
Lead Sponsor The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Collaborators: Guangzhou Reforgene Medicine Co., Ltd.
Conditions Alpha Thalassemia Hemoglobin H Constant Spring, Hemoglobinopathies, Hereditary Diseases
Enrollment 5 participants
Start Date 2023-10-08
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-03